RG-6540 is under clinical development by F. Hoffmann-La Roche and currently in Phase I for Primary Mediastinal B-Cell Lymphoma.

The therapeutic candidate is under development for the treatment of ovarian cancer. It comprises of induced pluripotent stem (iPS) cell derived natural killer (iNK) cell.

CD19-CD22 CAR-T cells is under clinical development by Shanghai Biomed-Union Biotechnology and currently in Phase II for Unspecified B-Cell Lymphomas.

Flonoltinib maleate is under clinical development by Chengdu Zenitar Biomedical Technology and currently in Phase II for Coronavirus Disease 2019 (COVID-19).

BM-219 is under clinical development by Suzhou Biomissile Biopharmaceutical and currently in Phase I for Coronavirus Disease 2019 (COVID-19).

Anti-CDH17 CAR-T Cells is under clinical development by UTC Therapeutics and currently in Phase I for Pancreatic Cancer.

NUV-868 is under clinical development by Nuvation Bio and currently in Phase II for Triple-Negative Breast Cancer (TNBC).

NA-731 is under clinical development by Biomed Industries and currently in Phase I for Traumatic Brain Injury.

Alphaf-001 is under clinical development by Alpha Fusion and currently in Phase I for Follicular Thyroid Cancer.

Biopharma and currently in Phase I for Metastatic Pancreatic Cancer. According to GlobalData, Phase I drugs for Metastatic Pancreatic Cancer have an 88% phase transition success rate (PTSR) indication ...

VI-0810 is under development for the treatment of diabetes. Vivus, a subsidiary of Icahn Enterprises LP, is developing drugs for the treatment of exocrine pancreatic insufficiency, obesity and ...